Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Ara-C scheduling: theoretical and experimental considerations

J W Gray, M G Pallavicini

Medical and Pediatric Oncology

|January 1, 1982

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Response to: 'Interpreting the guidelines for cleaning up after carbapenemase-producing organisms: the devil's in the dilution'.

The Journal of hospital infection·2016

Same author

The ErbB2ΔEx16 splice variant is a major oncogenic driver in breast cancer that promotes a pro-metastatic tumor microenvironment.

Oncogene·2016

Same author

Cleaning up after carbapenemase-producing organisms.

The Journal of hospital infection·2016

Same author

Functional proteomics identifies miRNAs to target a p27/Myc/phospho-Rb signature in breast and ovarian cancer.

Oncogene·2016

Same author

The protected environment for high-risk haematology patients: as safe as we think?

The Journal of hospital infection·2016

Same author

How do you solve a problem like multidrug-resistant Gram-negative bacteria?

The Journal of hospital infection·2015

Same journal

Kaposiform hemangioendothelioma and therapy with interferon-alpha.

Medical and pediatric oncology·2003

Same journal

Importance of informed consent in offering to return research results to research participants.

Medical and pediatric oncology·2003

Same journal

Tumor lysis syndrome and neuroblastoma.

Medical and pediatric oncology·2003

Same journal

High incidence of brain tumors of childhood in Hungary between 1989 and 2001.

Medical and pediatric oncology·2003

Same journal

Surviving childhood cancer: what next? Issues under consideration at the After Completion of Therapy (ACT) clinic in India.

Medical and pediatric oncology·2003

Same journal

Local control in childhood extremity sarcomas: salvaging limbs and sparing function.

Medical and pediatric oncology·2003

See all related articles

Optimizing cancer therapy schedules using cytokinetic principles can significantly improve patient outcomes. Randomly chosen schedules are unlikely to be effective, highlighting the need for precise timing based on cell behavior.

Area of Science:

Oncology
Cell Biology
Pharmacology

Background:

Cancer therapy scheduling significantly impacts treatment efficacy.
Cytokinetic data is crucial for designing effective therapeutic strategies.

Purpose of the Study:

To define a quantitative procedure for assessing the therapeutic acceptability of therapy schedules.
To explore the potential therapeutic gain from using cytosine arabinoside (Ara-C) in acute lymphoid leukemia (ALL).
To identify essential cytokinetic information for optimizing cancer therapy scheduling.

Main Methods:

Quantitative procedure development for therapy schedule evaluation.
Analysis of therapeutic gain in acute lymphoid leukemia (ALL) treated with cytosine arabinoside (Ara-C).
Experimental studies on the response of murine KHT sarcoma to Ara-C, including mid-treatment cytokinetic analysis.

Related Experiment Videos

Main Results:

Optimal therapy scheduling can lead to substantial improvements in cancer treatment.
Randomized therapy schedules are unlikely to yield significant therapeutic benefits.
Cytokinetic properties of normal tissues are critical in therapy design.
Therapy induces significant cytokinetic changes in tumors, such as increased cell cycle traverse rate and recruitment.

Conclusions:

Optimized cancer therapy scheduling based on cytokinetic principles offers significant therapeutic advantages.
Accurate cytokinetic information, including mid-treatment data, is vital for effective cancer therapy design and scheduling.
Understanding cell cycle dynamics is critical for maximizing treatment efficacy and minimizing toxicity.